Skip to content
Calculator
Guide

GLP-1s in type 1 diabetes: what the expert consensus and trials say

Last updated: October 27, 2026 · 10 min read · By the Grey Peptides Editorial Board

A woman wearing a continuous glucose monitor on her arm
Photo by Nutrisense Inc on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • No GLP-1 drug is approved for type 1 diabetes. Use is off-label, and the Wegovy label says it has not been evaluated in type 1.
  • An expert consensus from the Diabetes Technology Society concluded GLP-1 drugs may help adults with type 1 who use automated insulin delivery; a 2026 consensus report, endorsed by six professional bodies, gives guidance for safe use of GLP-1 and GLP-1/GIP drugs.
  • Trials show modest glucose improvements and meaningful weight loss, but both large liraglutide trials found more low blood sugar and, at the top dose, more high glucose with ketones.
  • Anyone with type 1 considering a GLP-1 drug needs a diabetes team: in the newer semaglutide and tirzepatide trials, insulin doses fell by about a fifth to a third.

Why people with type 1 are using GLP-1 drugs

Type 1 diabetes is caused by loss of the insulin-producing cells, so insulin is the core treatment. But overweight and obesity are common in type 1 and add to its raised cardiovascular risk (phase 2 trial; umbrella review) 1 2, and GLP-1 drugs lower weight. They are approved for type 2 diabetes, obesity and some related conditions, not for type 1 (consensus report) 3. The Diabetes Technology Society's consensus notes the growing interest in using GLP-1 drugs in type 1 despite their not being approved by FDA for it, in the absence of randomised trials documenting efficacy and safety in this group (consensus report) 4.

The labels reflect that gap. The Wegovy label states that its use in patients with type 1 diabetes or in combination with insulin has not been evaluated, while warning that combining it with insulin may increase the risk of hypoglycaemia, including severe hypoglycaemia 5.

The expert consensus reports

The Diabetes Technology Society convened three consensus meetings in 2024 of clinicians and researchers in diabetes technology, GLP-1 therapy and type 1 diabetes, focused on adults with type 1 who use automated insulin delivery (AID), the 'closed-loop' systems that adjust insulin from a continuous glucose monitor. The panel voted in favour of 31 recommendations and concluded that, in these adults, GLP-1 drugs have the potential to provide effective adjunct therapy and to improve glucose and metabolic outcomes without increasing the risk of severe hypoglycaemia or diabetic ketoacidosis (consensus report, published in the 2025 volume) 4.

Two points about it matter. It is a consensus of expert opinion, not a trial, written because trials were lacking. And several panel members disclosed research support or advisory roles with companies including Novo Nordisk and Lilly, which make GLP-1 drugs, as well as insulin-pump and sensor makers 4. Neither point invalidates it, but both are worth knowing.

A second consensus report followed in June 2026, written by a larger international panel and endorsed by six professional bodies, including the International Society for Pediatric and Adolescent Diabetes and Breakthrough T1D. It covers GLP-1 and dual GLP-1/GIP drugs, says approval for type 1 has not been achieved partly because the trials so far are small and inconsistent, names hypoglycaemia and hyperglycaemia-related ketosis as the potential safety risks, and gives practical guidance on insulin dose changes and glucose and ketone monitoring (consensus report) 3.

The first big trials: liraglutide in ADJUNCT ONE and TWO

The largest trials are older and used liraglutide. In ADJUNCT ONE, 1,398 adults with type 1 were randomised to liraglutide at one of three doses or placebo, added to treat-to-target insulin for 52 weeks. HbA1c fell slightly more with the higher doses, by 0.20 percentage points more than placebo at 1.8 mg, and insulin doses and body weight fell too. But symptomatic hypoglycaemia increased in all liraglutide groups, and high glucose with ketosis increased at 1.8 mg; the authors concluded these limited clinical use in type 1 (randomised trial; two of the authors were Novo Nordisk employees) 6.

ADJUNCT TWO, with 835 adults on capped insulin doses for 26 weeks, found similar modest HbA1c reductions and weight loss of up to 5.1 kg, with improved quality of life. It also found the risks that worry clinicians: more symptomatic hypoglycaemia with liraglutide 1.2 mg than placebo (21.3 against 16.6 events per patient-year) and more episodes of high glucose with ketosis with 1.8 mg (0.5 against 0.1 events per patient-year) (randomised trial; three authors were Novo Nordisk employees) 7. A 2023 meta-analysis of 24 studies and 3,377 patients found liraglutide had the most evidence, with effects on HbA1c, weight and insulin dose that grew with the dose. Higher doses also raised the odds of nausea and of ketosis (odds ratio 1.8), while severe and symptomatic hypoglycaemia were not significantly increased (meta-analysis) 8.

Semaglutide with automated insulin delivery

Newer trials pair semaglutide with AID systems, the setting the consensus addresses. In a double-blind crossover trial of 28 adults (24 completed), semaglutide increased time spent in the target glucose range by 4.8 percentage points compared with placebo. There was no diabetic ketoacidosis or severe hypoglycaemia, but there were two episodes of recurrent ketosis with normal glucose, without acidosis, during semaglutide use (randomised crossover trial) 9.

ADJUST-T1D randomised 72 adults with type 1 and obesity using AID to weekly semaglutide up to 1 mg or placebo for 26 weeks. The combined goal, more than 70% of time in range, less than 4% time below range and at least 5% weight loss, was met by 36% on semaglutide and none on placebo. HbA1c was 0.3 points lower, time in range 8.8 points higher and weight 8.8 kg lower. There were two severe hypoglycaemia events in each group and no diabetic ketoacidosis (randomised trial, funded by Breakthrough T1D) 10.

StudyPeopleMain findings
ADJUNCT ONE, liraglutide (2016)1,398 adults, 52 weeksHbA1c 0.20 points lower than placebo at 1.8 mg; weight and insulin doses reduced; more symptomatic hypoglycaemia, and more high glucose with ketosis at 1.8 mg
ADJUNCT TWO, liraglutide (2016)835 adults, 26 weeksHbA1c and weight lower; more symptomatic hypoglycaemia at 1.2 mg and more high glucose with ketosis at 1.8 mg
Crossover, semaglutide with automated insulin delivery (2025)28 adults (24 completed)Time in target range up 4.8 points; no DKA; two episodes of ketosis without acidosis on semaglutide
ADJUST-T1D, semaglutide with automated insulin delivery (2025)72 adults with obesity, 26 weeks36% vs 0% met a combined glucose-and-weight goal; weight 8.8 kg lower; no DKA
Phase 2 trial, tirzepatide (2026)24 adults with obesity, 12 weeksWeight 8.7 kg lower than placebo; insulin dose 35.1% lower; no significant adverse events
Real-world comparison, Kuwait (2026)250 people with a BMI of 27 or more (35 on tirzepatide), 12 monthsWeight loss greatest with tirzepatide (10.9%); no severe hypoglycaemia or DKA reported

Tirzepatide and real-world use

Tirzepatide, which acts on both GLP-1 and GIP receptors, has one small randomised trial in type 1. In a 12-week phase 2 trial run from Sydney, 24 adults with type 1 and a BMI over 30 were given tirzepatide (2.5 mg, then 5 mg weekly) or placebo; 22 finished. Weight fell 8.7 kg more than with placebo, HbA1c was 0.4 points lower (P = 0.05), total daily insulin fell 35.1% more, and there were no significant adverse events in either group (randomised trial) 1. Larger trials are under way 3.

A real-world study from Kuwait of 250 people with type 1 and a BMI of 27 or more (35 on tirzepatide, 36 on semaglutide, 97 on liraglutide and 82 on usual care) found that over 12 months tirzepatide gave the greatest weight loss (10.9%), followed by semaglutide (9.9%) and liraglutide (7.1%), with modest HbA1c reductions (0.65, 0.33 and 0.23 points), and no severe hypoglycaemia or ketoacidosis was reported (observational study) 11. Observational data cannot rule out that the people chosen for each drug differed.

The risks: low blood sugar, ketones and insulin doses

Three risks dominate. Low blood sugar: the Wegovy label warns that use with insulin may raise the risk of hypoglycaemia, including severe hypoglycaemia, and says to consider reducing the insulin dose when starting 5; both ADJUNCT trials found more symptomatic hypoglycaemia with liraglutide (in ADJUNCT TWO, significantly so at 1.2 mg) 6 7. Ketones: both found more high glucose with ketosis at the top dose 6 7, and the 2026 consensus names hyperglycaemia-related ketosis as a potential risk 3. The newer AID trials saw no diabetic ketoacidosis, though the crossover trial recorded two episodes of ketosis without acidosis 9 10, and the 2024 consensus judged the risk not increased in AID users 4; the trials were small.

Insulin adjustment is therefore the practical heart of it, and the 2026 consensus gives guidance on insulin dose changes and on glucose and ketone monitoring for people with type 1 on these drugs 3. Our guide to peptides and blood sugar explains the interaction in general terms.

How much insulin changes

A post hoc analysis of ADJUST-T1D, comparing the semaglutide and placebo groups, quantified the insulin change. Over 26 weeks, total daily insulin fell 22.6%, driven more by mealtime (bolus) insulin, which fell 30.5%, than by background (basal) insulin, which fell 15.6%. Early in treatment most of the fall was a direct effect of the drug rather than of weight loss (secondary analysis; two authors were from Breakthrough T1D, the trial's funder) 12. In the tirzepatide phase 2 trial, total daily insulin fell 35.1% more than with placebo in 12 weeks 1. That is a large shift for anyone dosing by injection.

What happens when people stop

The glucose benefit may not last after stopping. In the 12 weeks after ADJUST-T1D ended, the 16 participants who had been on semaglutide and stopped saw a larger fall in time in range than the 22 who had been on placebo (a median change of -3.6 against +1.5 percentage points) and more glucose variability (follow-up analysis) 13. Anyone starting a GLP-1 drug in type 1 should plan with their team for how insulin will be readjusted if they stop, whether by choice, side effects or a supply problem.

What reviews of all the evidence say

A 2026 umbrella review that pooled systematic reviews, meta-analyses and genetic studies found GLP-1 drugs in type 1 gave clinically meaningful weight loss of about 4 to 5 kg and lower insulin doses, statistically significant but modest HbA1c reductions of 0.2 to 0.3 points, and no improvement in time in range. Severe hypoglycaemia was not increased, but time below range and gastrointestinal side effects were more frequent, and evidence on ketoacidosis was inconsistent across studies (umbrella review) 2. The two newer semaglutide trials with automated insulin delivery did find more time in range 9 10, but they are small. The review also notes that direct cardiovascular benefits in type 1 remain unproven without dedicated outcome trials 2, which matters because heart protection is one of the main reasons people with type 1 are interested in these drugs.

Off-label prescribing and access

Because no GLP-1 drug is approved for type 1, prescribing is off-label. The 2026 consensus notes that people with type 1 can already get these drugs through their approval for overweight and obesity, but that without a type 1 approval they may miss the education and support from diabetes professionals needed to manage the expected insulin changes 3. Compounded and research products carry their own problems, which our guide to compounded and research tirzepatide covers; the trials used approved products, not these. Our semaglutide brands guide explains which approved product is which.

Questions to ask your diabetes team

  • Do I have a reason, such as obesity, that makes a GLP-1 drug worth trying, and is it covered for that use?
  • How should my insulin doses change when I start, and who will adjust them?
  • Does my AID system or injection regimen affect the risk?
  • How and when should I check ketones, and what should I do if they are raised?
  • What should make me stop the drug and call you?

The bottom line

GLP-1 drugs are not approved for type 1 diabetes, but evidence is building. Expert consensus reports concluded they may help adults with type 1, particularly with automated insulin delivery, and trials show modest glucose benefits and meaningful weight loss, with no ketoacidosis in the newest small studies. The large liraglutide trials found more low blood sugar, and more ketosis at the top dose. This is a treatment to start with a diabetes team, insulin plan in hand, not alone.

Frequently asked questions

Can people with type 1 diabetes take Ozempic?

No GLP-1 drug is approved for type 1 diabetes, so use is off-label. Trials and an expert consensus suggest benefits alongside automated insulin delivery, with careful insulin adjustment.

Do GLP-1 drugs cause DKA in type 1 diabetes?

Both ADJUNCT trials found more high glucose with ketosis at liraglutide 1.8 mg. Newer small semaglutide trials with automated insulin delivery found no DKA (one recorded two episodes of ketosis without acidosis), and the 2024 consensus judged the risk not increased in that setting.

How much weight do people with type 1 lose on semaglutide?

In ADJUST-T1D, adults with obesity on automated insulin delivery lost 8.8 kg more with semaglutide than placebo over 26 weeks.

Is tirzepatide used in type 1 diabetes?

Off-label. A 12-week phase 2 trial in 24 adults with type 1 and obesity found 8.7 kg more weight loss than placebo, and a 2026 real-world study found 10.9% weight loss over 12 months.

What did the expert consensus recommend?

The Diabetes Technology Society panel voted in favour of 31 recommendations and concluded GLP-1 drugs may provide effective adjunct therapy for adults with type 1 using automated insulin delivery. A 2026 consensus report gives practical guidance on insulin changes and glucose and ketone monitoring.

Sources

  1. Snaith, J. R., et al. (2026). Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. Diabetes Care, 49(1), 161-170. PMID: 41264593 · doi:10.2337/dc25-2379
  2. Wójcik-Sosnowska, E., et al. (2026). Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes. Int J Mol Sci, 27(9). PMID: 42123472
  3. Garg, S. K., et al. (2026). Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use. Diabetes Technology and Therapeutics, published online June 5, 2026. PMID: 42246488 · doi:10.1177/15209156261449879
  4. Shah, V. N., et al. (2025). Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. J Diabetes Sci Technol, 19(1), 191-216. PMID: 39517127
  5. Novo Nordisk. WEGOVY (semaglutide) US prescribing information, Warnings and Precautions 5.4: use with insulin may increase the risk of hypoglycemia, including severe hypoglycemia; use in type 1 diabetes or with insulin has not been evaluated; consider reducing the insulin dose when starting. DailyMed set ee06186f, version 19, published June 30, 2026; read October 3, 2026, re-read October 27, 2026. DailyMed
  6. Mathieu, C., et al. (2016). Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 39(10), 1702-10. PMID: 27506222
  7. Ahrén, B., et al. (2016). Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care, 39(10), 1693-701. PMID: 27493132
  8. Park, J., et al. (2023). Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. J Clin Endocrinol Metab, 109(1), 279-292. PMID: 37561012
  9. Pasqua, M. R., et al. (2025). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med, 31(4), 1239-1245. PMID: 39794615
  10. Shah, V. N., et al. (2025). Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid, 4(8), EVIDoa2500173. PMID: 40550013
  11. Al Ozairi, E., et al. (2026). Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide. Diabetes Obes Metab, 28(1), 166-173. PMID: 41048008
  12. Karakus, K. E., et al. (2026). Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. Diabetes Care, 49(5), 718-723. PMID: 41429002
  13. Montaser, E., et al. (2026). Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study. Diabetes Obes Metab, . PMID: 42675550

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead